Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Exel save search
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
Published: 2023-12-04 (Crawled : 13:30) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.46%
H: 2.75%
C: 2.7%
ellar-305 cancer trial
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
Published: 2023-11-10 (Crawled : 19:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.1%
H: 0.33%
C: 0.0%
ellar-001 kidney cancer expansion trial results
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.555 -0.06% -0.06% 590K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Global Liver Cancer Drugs Strategic Market Report to 2030: Targeted Therapies Grow in Popularity
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
liver global report cancer market
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Published: 2023-01-10 (Crawled : 15:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.18%
H: 2.14%
C: 2.08%
treatment license agreement cancer
Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: -0.74%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -0.25%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.08%
H: 0.21%
C: -0.1%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.01%
H: 0.08%
C: -0.95%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.16%
C: -0.47%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.04%
H: 0.21%
C: -0.25%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: 0.61%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.32%
H: 2.91%
C: 2.75%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.46%
H: 0.38%
C: 0.01%
global disease report therapeutics cancer market
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
Published: 2022-12-22 (Crawled : 14:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -0.38%
H: 1.37%
C: 1.21%
ellar-304 kidney trial cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Kidney Cancer Drugs Market Global Report 2022: Featuring Pfizer, Amgen, Bayer, Novartis, F. Hoffmann-La Roche & More
Published: 2022-10-28 (Crawled : 13:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.87%
H: 2.31%
C: 2.1%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.74%
H: 1.34%
C: 1.16%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.92%
H: 1.8%
C: 1.53%
global report kidney roche cancer market
Global Kidney Cancer Drugs Market to Surpass US$ 9.60 Billion by 2030 - Coherent Market Insights
Published: 2022-08-10 (Crawled : 18:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.32%
H: 0.16%
C: -0.45%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 3.13%
H: 0.69%
C: -10.22%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.58%
H: 1.06%
C: 0.91%
global kidney cancer market
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Published: 2022-07-07 (Crawled : 10:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -2.95%
H: 2.14%
C: 0.79%
license therapeutics agreement cancer therapy
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 5.5%
H: 0.0%
C: 0.0%
ellar-303 xl092 trial cancer phase 3
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.14%
H: 1.53%
C: 1.48%
cabometyx positive cancer chmp
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.42%
H: 0.48%
C: -0.41%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -1.91%
osmic-312 liver trial cancer phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.